Clinical characteristics affecting weight loss in an East Asian population receiving semaglutide: A STEP 6 subgroup analysis

What Was Tested

The paper reports a study of Semaglutide, published as a randomized controlled trial.

To explore the effects of semaglutide versus placebo on body weight (BW) by subgroups of baseline characteristics.

Who Took Part

The abstract describes 6, adults taking part.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

A subset of Japanese participants with type 2 diabetes (T2D) was also included.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The adults were allocated by chance, so the Semaglutide group and the comparison group should start out alike.

Neither the adults nor the staff measuring them knew who was on Semaglutide, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Semaglutide could be set against what happens without it.

In this post-hoc analysis, change from baseline in BW (%) was assessed by subgroups of baseline characteristics including baseline BW, body mass index, age, sex, glycemic status, dyslipidemia, and hypertension.

What Was Measured

PubMed files the paper under topics including Body Mass Index, Diabetes Mellitus, Type 2, East Asian People, Glucagon-Like Peptides, Hypoglycemic Agents, Japan and Obesity.

The authors tagged it with the keywords Clinical characteristics, GLP-1, Type 2 diabetes and Weight management.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Semaglutide in 6, adults.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (Obesity research & clinical practice), a journal based in Netherlands.

More context: the Semaglutide compound page, all human trials.